Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (öffnet neues Fenster)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Quelle‎: Cancer 2013;119(21):3784-7.

Indiziert‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (öffnet neues Fenster)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (öffnet neues Fenster)

Chakrabarti S, Varma S, Singh S, Kumari S

Quelle‎: Eur J Haematol 1998;60(5):313-4.

Indiziert‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (öffnet neues Fenster)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (öffnet neues Fenster)

Delaney M, Matthews DC, Gernsheimer TB

Quelle‎: Pediatr Blood Cancer 2017;64(12):e26641.

Indiziert‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (öffnet neues Fenster)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (öffnet neues Fenster)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Quelle‎: J Urol 2010;184(3):1152-7.

Indiziert‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (öffnet neues Fenster)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (öffnet neues Fenster)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Quelle‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indiziert‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (öffnet neues Fenster)

Pediatric off-label use of recombinant factor VIIa. (öffnet neues Fenster)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Quelle‎: Pediatrics 2009;123(3):1066-72.

Indiziert‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (öffnet neues Fenster)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (öffnet neues Fenster)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Quelle‎: Indian J Pediatr 2011;78(8):961-8.

Indiziert‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (öffnet neues Fenster)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (öffnet neues Fenster)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Quelle‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indiziert‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (öffnet neues Fenster)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (öffnet neues Fenster)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Quelle‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Indiziert‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (öffnet neues Fenster)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (öffnet neues Fenster)

Das P, Carcao M, Hitzler J

Quelle‎: Pediatr Blood Cancer 2006;47(2):206-9.

Indiziert‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (öffnet neues Fenster)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (öffnet neues Fenster)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Quelle‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Indiziert‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (öffnet neues Fenster)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (öffnet neues Fenster)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Quelle‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Indiziert‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (öffnet neues Fenster)

Off-label use of recombinant factor VIIa in pediatric patients. (öffnet neues Fenster)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Quelle‎: Pediatrics 2012;129(6):e1533-40.

Indiziert‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (öffnet neues Fenster)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (öffnet neues Fenster)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Quelle‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Indiziert‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (öffnet neues Fenster)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (öffnet neues Fenster)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Quelle‎: Med Oncol 2010;27(1):16-9.

Indiziert‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (öffnet neues Fenster)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (öffnet neues Fenster)

Ucar C, Caliskan U

Quelle‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Indiziert‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (öffnet neues Fenster)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (öffnet neues Fenster)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Quelle‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indiziert‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (öffnet neues Fenster)

The use of DDAVP in children with bleeding disorders. (öffnet neues Fenster)

Ben-Ami T, Revel-Vilk S

Quelle‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Indiziert‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (öffnet neues Fenster)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (öffnet neues Fenster)

Kobrinsky NL, Tulloch H

Quelle‎: J Pediatr 1988;112(6):993-6.

Indiziert‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (öffnet neues Fenster)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (öffnet neues Fenster)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Quelle‎: J Pediatr Surg 2013;48(3):689-94.

Indiziert‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (öffnet neues Fenster)